Platelet Rich Plasma and Growth Factor Treatments 2.01.24
Effective date
Jan 22, 2026
Identified
Jun 20, 2026
Summary
Policy 2.01.24, Platelet Rich Plasma and Growth Factor Treatments, states that platelet-rich plasma (PRP) and autologous platelet-derived preparations, including basic fibroblast growth factor, epidermal growth factor, and placental angiogenic growth factors, are investigational for all indications. The 01/22/26 annual update changed the policy title and deleted the policy statements for becalpermin gel. The policy also states that the AAOS guidelines for osteoarthritis of the hip and glenohumeral joint, and for rotator cuff injuries, do not recommend PRP for these conditions.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.
01Already effective January 22, 2026: Billing team, the policy lists CPT 0232T, HCPCS G0460, G0465, P9020, and S9055 as (E/I) experimental or investigational.
02G0465 applies to diabetic chronic wounds and ulcers using an FDA-cleared device, and G0460 applies to nondiabetic chronic wounds and ulcers.
03Services are contract dependent: if a product does not cover a service, the medical policy criteria do not apply, and if a commercial product covers a specific service, the medical policy criteria apply to that benefit.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.